Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Abacavir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 345Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lupin gets USFDA nod for generic HIV drug
    Lupin gets USFDA nod for generic HIV drug

    24 Jan 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-usfda-nod-for-generic-hiv-drug/articleshow/117517932.cms

    ECONOMICTIMES
    24 Jan 2025
    Share Share
    Lupin receives FDA tentative approval for HIV treatment generic
    Lupin receives FDA tentative approval for HIV treatment generic

    07 Dec 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/lupin-receives-u-s-fda-tentative-approval-for-hiv-treatment-generic/

    EXPRESSPHARMA
    07 Dec 2024
    Share Share
    ACTG Links Abacavir Use To Higher Cardiovascular Risk In HIV Patients
    ACTG Links Abacavir Use To Higher Cardiovascular Risk In HIV Patients

    23 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/23/2916996/0/en/ACTG-Presents-Data-Analysis-at-AIDS-2024-Showing-Association-between-Elevated-Risk-of-Cardiovascular-Events-and-Abacavir-Use-Among-People-Living-with-HIV.html

    GLOBENEWSWIRE
    23 Jul 2024
    Share Share
    Viatris Announces U.S. FDA Approval of a Paediatric Formulation of Abacavir
    Viatris Announces U.S. FDA Approval of a Paediatric Formulation of Abacavir

    05 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viatris-announces-us-fda-tentative-approval-of-a-paediatric-formulation-of-abacavir-abcdolutegravir-dtglamivudine-3tc-a-once-daily-treatment-for-children-living-with-hiv-301917144.html

    PR NEWSWIRE
    05 Sep 2023
    Share Share
    Cipla, DNDi launch 4-in-1 antiretroviral treatment for young children with HIV
    Cipla, DNDi launch 4-in-1 antiretroviral treatment for young children with HIV

    14 Jun 2022

    // EXPRESS PHARMA

    https://www.expresspharma.in/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-young-children-with-hiv-in-south-africa/

    EXPRESS PHARMA
    14 Jun 2022
    Share Share
    ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
    ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV

    30 Mar 2022

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv/

    PRESS RELEASE
    30 Mar 2022
    Share Share